抗凝治疗的新革命-利伐沙班

The three main factors of venous thrombosis are venous blood hypercoagulability, blood flow stasis, and vascular endothelial cell damage. Therefore, anticoagulation, antiplatelet aggregation, and thrombolysis are currently the main treatments. Traditional low molecular weight heparin sodium plays a very important role in preventing venous thrombosis after lower limb surgery, and enoxaparin is one of the representative drugs. As a new generation of anticoagulant drugs, the new generation of Factor

Rivaroxaban is a highly bioavailable factor Xa inhibitor that can selectively block the active site of factor Xa and activate factor Xa through endogenous and exogenous pathways, playing an important role in the coagulation cascade. Compared with traditional anticoagulant drugs, it is more effective, safer and easier to use. It is often used for the secondary prevention of patients with acute lower extremity deep vein thrombosis (LEDVT), pulmonary thromboembolism (PTE), non-valvular atrial fibrillation and acute coronary syndrome.

Some people have found that Rivaroxaban combined with catheter thrombolysis can further improve the therapeutic effect and reduce the difference in circumference between the affected limb and the healthy limb compared with the use of catheter thrombolysis alone in the treatment of LEDVT. Others have also found that rivaroxaban combined with catheter thrombolysis can significantly improve the efficacy of LEDVT and accelerate the elimination of swelling in the affected limb. The study found that Angiojet combined with rivaroxaban can significantly improve the efficacy of treating LEDVT compared with Angiojet alone. The difference in circumference between the affected limb and the healthy limb at 20 cm above the knee and 15 cm below the knee is significantly reduced, and the recurrence rate is also significantly reduced.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.